Conduent stock touches 52-week low at $2.93 amid market challenges

Published 21/03/2025, 14:36
Conduent stock touches 52-week low at $2.93 amid market challenges

Conduent Incorporated (NASDAQ:CNDT), a provider of diversified business services, has seen its stock price touch a 52-week low, reaching $2.93. According to InvestingPro data, the company trades at a P/E ratio of 1.3, suggesting a notably low earnings multiple despite concerning indicators about its financial health. This latest price level reflects a challenging period for the company, with a more severe year-to-date decline of 26.49%. Investors are closely monitoring Conduent’s performance as it navigates through the current market conditions, with InvestingPro analysis revealing concerns about cash burn and potential difficulties with debt payments. The platform offers 8 additional key insights about CNDT’s financial position through its comprehensive Pro Research Report. The company’s ability to rebound from this low will be watched with keen interest as market participants consider the firm’s strategic initiatives and potential for recovery, particularly given analysts’ expectations of negative earnings per share for the upcoming fiscal year.

In other recent news, Conduent Incorporated announced its fourth-quarter 2024 earnings, revealing a slight miss on earnings per share (EPS), which stood at -$0.15 compared to the forecasted -$0.12. The company’s revenue also fell short of expectations, coming in at $800 million against an anticipated $806.33 million. Conduent’s overall performance for 2024 showed a 4.3% decline in revenue, amounting to $3.176 billion compared to the previous year. In terms of strategic developments, the company is focusing on leveraging AI technologies and expanding offshore capabilities to improve its financial position. Conduent has also provided cautious guidance for 2025, with a revenue target range of $3.100-$3.250 billion. In other company news, Ireland’s Health Service Executive has adopted Conduent’s Maven Disease Surveillance & Outbreak Management System, marking its first deployment in the European Union. This system aims to enhance disease tracking and management capabilities by automating data coordination among healthcare professionals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.